Nexgenix Pharmaceuticals, LLC

NexGenix is a privately-held drug discovery and development company focused on the "next generation" of targeted therapies for cancer, neurodegenerative diseases, neurofibromatosis and related genetically-determined disorders. The company has acquired, through in-licensing and research collaboration, a robust structural chemistry platform in resorcylic macrolides, highly potent inhibitors of heat shock protein 90 (Hsp90). The concept that numerous diseases, including cancer, neurofibromatosis, amyotrophic lateral sclerosis (Lou Gehrig's disease) and Parkinson's disease may be caused by misfolding of various proteins presents a unique opportunity for drug development for these varied disorders. NexGenix's novel Hsp90 inhibitors, based on the highly potent compound radicicol, have the potential to be best in class drugs. NexGenix also has a program in kinase inhibitors and is developing a non-surgical treatment for dermal neurofibromas, the commonest lesion in the genetic disorder neurofibromatosis type 1 (NF1), based on a vascular disruption mechanism. NexGenix has world-class scientific advisors and collaborators in the areas of protein folding, kinase signaling and oncogenesis, and neurodegenerative diseases. The company additionally has a growing portfolio of intellectual property covering its key efforts.